Wayne Koberstein
-
Companies To Watch: Ocelot Bio
1/3/2023
Ocelot Bio is focusing a single drug on multiple complications of end-stage liver disease.
-
Biopharma Public Opinion, Pricing, Politics
12/1/2022
Biopharma sustainability will require the industry not shy from public opinion, but meet it head on. To win short-term battles, however impressively as with creation of the COVID vaccines, may not be enough to secure total victory.
-
Pioneering In-House, Continuous Manufacturing
11/1/2022
Patricia Hurter of Lyndra Therapeutics believes having an in-house continuous manufacturing capability delivers the flexibility, speed, and reliability needed for development and production of those long-acting drugs.
-
Companies To Watch: iTolerance
11/1/2022
iTolerance is dedicated to curing diabetes and other conditions by inducing local immune tolerance in implantation.
-
Companies To Watch: CytoAgents
10/3/2022
CytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.
-
The Discovering CEO
10/3/2022
In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.
-
Nonprofit Pursues Oncology Drugs
9/1/2022
RebootRX believes that many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.
-
Companies To Watch: Viking Therapeutics
9/1/2022
Viking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.
-
Companies To Watch: Priothera
8/1/2022
Priothera is bent on boosting the safety and effectiveness of hematopoietic stem cell transplantation for blood cancers.
-
Living Diversity, Inside Mink Therapeutics
8/1/2022
We sought out a biopharma enterprise where diversity always has been an operating principle, where it feeds the company’s intellectual life and creative culture, and where it is demonstrable yet still evolving.